[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-wound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-wound":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100358467","phase-2-autologous-volar-fibroblast-injection-into-the-stump-site-of-amputees-100358467",false,"NCT03947450","Autologous Volar Fibroblast Injection Into the Stump Site of Amputees","Inclusion Criteria:\n\nPatients interested in study participation must meet all of the following inclusion criteria:\n\n* May be male or female\n* Must be between 18 years and 65 years of age\n* Must have a below the knee amputation.\n* Must be using a prosthetic for the vicinity of 3 months or have had osteo-integration of a prosthetic in place for 1 month.\n* In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality.\n* Be able to comprehend the informed consent document and provide consent for participation\n* Females of childbearing potential must:\n\n  * have a negative pregnancy test at screening\n  * agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study\n  * be willing to use a reliable form of contraception during the study\n* Be willing and able to comply with the scheduled visits, biopsy\u002Finjection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be ineligible for study participation:\n\n* A skin erosion deeper than the skin dermis.\n* Having received any investigational drug within 30 days prior to study entry\n* An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, hetastarch, or EMLA (lidocaine 2.5% and prilocaine 2.5%).\n* Pregnant, lactating, or trying to become pregnant\n* A history of keloid formation\n* Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, HTLV I\u002FII, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate.\n* Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus.\n* Presence of necrotic ischemic tissue on any stump ulcers, and\u002For capillary refill on stump skin of greater than 3 seconds\n* Active infection of the residual limb.\n* Active smoker during the study\n* We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation.\n* Recent amputee who has not yet been approved to use a prosthetic.\n* Use of a prosthetic for less than 3 months.\n* Amputees with neuromas of the terminal limb within the last 3 months.\n* Known bleeding disorder.\n* For those receiving Bellafill\u002Fcollagen skin test: history of serious allergy, such as anaphylaxis.\n* For whole stump injections: Have a history of congenital or idiopathic methemoglobinemia, glucose-6-phosphate deficiencies, or use of medications associated with drug-induced methemoglobinemia. (specifically: Sulfonamides, Acetaminophen, Acetanilid, Aniline dyes, Benzocaine, Chloroquine, Dapsone, Naphthalene, Nitrates and Nitrites, Nitrofurantoin, Nitroglycerin, Nitroprusside, Pamaquine, Para-aminosalicylic acid, Phenacetin, Phenobarbital, Phenytoin, Primaquine, or Quinine.)",true,"ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study is a clinical trial testing the safety and efficacy of volar fibroblast (skin cells from the palm or sole) injections for thickening the epidermal (skin) layer at the stump site in people with below the knee amputations. The study will enroll adults seen at Johns Hopkins.",[27,28,29],"Amputation","Skin Wound","Stem Cell",[31,32,33,34,35],"amputation","stem cells","autologous fibroblast","skin wound","skin breakdown","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-09","ACTUAL",{"date":42,"type":40},"2019-09-05",{"date":44,"type":21},"2028-04-01",{"name":46,"class":47},"Johns Hopkins University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100514909","umbilical-cord-stem-cells-for-skin-grafts-in-donor-site-wounds-100514909","NCT05984628","Umbilical Cord Stem Cells for Skin Grafts in Donor Site Wounds","Inclusion Criteria:\n\n1. Patients between 18 and 60 years old with extensive scars, large benign tumors, or fresh wounds on the body surface.\n2. Patients who undergo medium-thickness skin graft surgery (donor site can be from the thigh, abdomen, or back).\n3. Participants who have a thorough understanding of the study objectives, significance, implementation plan, potential benefits, risks involved, measures to address risks, and the rights and obligations of the subjects (including privacy protection and the right to withdraw), and are willing to participate in this clinical study and can cooperate effectively.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are not suitable for inclusion:\n\n1. Hypertension, hypotension, heart disease (including history of myocardial ischemia, coronary heart disease, myocarditis).\n2. Liver or kidney dysfunction.\n3. Infectious diseases (including viral hepatitis, syphilis, HIV\u002FAIDS, etc.).\n4. Venous thrombosis, thoracic or abdominal aortic aneurysm, aortic dissection.\n5. Blood disorders (abnormal coagulation function, anemia, leukemia, polycythemia vera, aplastic anemia, etc.).\n6. Allergic conditions (urticaria, bronchial asthma, history of allergic reactions to two or more drugs or foods).\n7. Respiratory system diseases (chronic bronchitis, emphysema, bronchiectasis, respiratory failure, chronic obstructive pulmonary disease, interstitial pneumonia).\n8. Digestive system diseases (severe gastric or duodenal ulcers, chronic gastritis, chronic pancreatitis).\n9. Urinary system diseases (chronic urinary tract infections, nephritis, nephrotic syndrome).\n10. Endocrine system diseases (hyperthyroidism, diabetes, acromegaly, pituitary diseases, adrenal diseases, diabetes insipidus).\n11. Organic neurological disorders or psychiatric illnesses (encephalitis, sequelae of traumatic brain injury, epilepsy, schizophrenia, hysteria, depression, severe insomnia, neurasthenia).\n12. Chronic skin diseases (especially infectious, allergic, and inflammatory systemic skin diseases, such as extensive eczema, pemphigus, pemphigoid).\n13. Autoimmune diseases and collagen diseases (such as systemic lupus erythematosus, dermatomyositis, scleroderma).\n14. History of long-term smoking, alcohol abuse, or drug addiction.\n15. History of major surgeries (such as gastric, lung, splenic, renal, or liver resection).\n16. History of other significant malignant tumors.\n17. Blood donation or organ transplantation within the past 5 years.\n18. Pregnancy, lactation, menstrual period, or within 1 year after termination of pregnancy.\n19. Previous circumstances of being rejected for voluntary blood donation.\n20. Other situations deemed unsuitable for participation in this study by the investigators.","60 Years",{"count":57,"type":21},88,[59],"NA","The goal of this clinical trial is to evaluate the safety and effectiveness of human umbilical cord mesenchymal stem cell (hUCMSC) therapy in patients undergoing medium-thickness skin grafts for donor site wounds. The study aims to answer the following main questions:\n\n* Question 1: Does hUCMSC therapy improve the healing quality and speed of donor site wounds in comparison to standard treatment?\n* Question 2: Does hUCMSC therapy reduce scar formation in the donor site wounds?\n\nParticipants in this study will undergo medium-thickness skin grafts, and those in the treatment group will receive hUCMSC therapy. The main tasks for participants will involve regular follow-up visits, monitoring of wound healing progress, and assessment of any potential side effects or complications associated with the therapy.\n\nIn order to evaluate the effectiveness of hUCMSC therapy, researchers will compare the treatment group receiving hUCMSC therapy with a control group that receives standard treatment alone. The aim is to determine if the use of hUCMSC therapy leads to improved healing outcomes and reduced scar formation compared to the standard treatment group.",[28,62],"Scar, Hypertrophic",[64,28,62,65],"hUCMSC","Stem cell","2025-06-29",{"date":68,"type":40},"2025-07-02",{"date":70,"type":40},"2021-10-20",{"date":72,"type":21},"2026-10-20",{"name":74,"class":47},"Fujian Medical University Union Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":17,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":48},"100570940","to-evaluate-the-skin-closure-time-parents-satisfaction-post-operative-mental-health-wound-cosmesis-and-wound-complication-of-skin-closure-using-adhesive-glue-adhesive-tape-and-suture-in-paediatric-surgery-patients-100570940","NCT06713772","To Evaluate The Skin Closure Time, Parents' Satisfaction, Post Operative Mental Health, Wound Cosmesis and Wound Complication Of Skin Closure Using Adhesive Glue, Adhesive Tape And Suture In Paediatric Surgery Patients","A Randomised Controlled Trial To Evaluate The Skin Closure Time, Parents' Satisfaction, Post Operative Mental Health, Wound Cosmesis and Wound Complication Of Skin Closure Using Adhesive Glue, Adhesive Tape And Suture In Paediatric Surgery Patients","Inclusion Criteria:\n\n* patients aged 18 years or less\n* clean and clean contaminated surgery\n* wound length of 1-10cm\n* surgical wound amenable to closure with the three skin closure techniques\n\nExclusion Criteria:\n\n* scrotal or penile incision\n* contaminated or dirty wound\n* repeated surgical procedures at the surgical site\n* wound that is not amenable to primary closure with the three techniques\n* patient with known allergy to cyanoacrylate\n* patients receiving chemotherapy, immunosuppression, systemic corticosteroids, or with known malignancy","1 Day",{"count":84,"type":21},90,[59],"This study is a randomised controlled trial to evaluate the skin closure time, parents' satisfaction, post operative mental health, wound cosmesis and wound complication of skin closure using adhesive glue, adhesive tape and suture in paediatric surgery patients.\n\nPrimary objective is to compare skin closure time required by using adhesive glue, adhesive tape and suture. Secondary objectives are to compare parents' satisfaction, post operative mental health, wound cosmesis and wound complication of skin closure using adhesive glue, adhesive tape and suture in paediatric surgery patients.\n\nThis study will be conducted from 26th August 2024 to 31st May 2025. It will take place at Hospital Pakar Kanak-Kanak UKM (HPKK), involving paediatric surgery patients undergoing clean or clean contaminated surgeries.\n\nThe sample size calculated is 30 per group, a total of 90 patients for three groups. The sampling method used is simple random sampling method.\n\nIn group A, skin will be closed using adhesive glue (Dermabond Mini, 0.36ml, Ethicon Johnson and Johnson, Somerville, New Jersey, USA). Skin closure in group B will be done using adhesive tape (Steri-StripsTM (3M, St. Paul, Minnesota, USA). In group C, skin will be closed using suture (Monosyn, B.Braun, 118 Pfieffewiesen, Melsungen, Germany) 4\u002F0.",[28],"2024-11-27",{"date":90,"type":40},"2024-12-03",{"date":92,"type":40},"2024-08-26",{"date":94,"type":21},"2025-05-31",{"name":96,"class":47},"National University of Malaysia"]